- 专利标题: Vitamin E-nucleoside prodrugs
-
申请号: US15516657申请日: 2015-10-08
-
公开(公告)号: US10071112B2公开(公告)日: 2018-09-11
- 发明人: Richard Daifuku
- 申请人: EPIGENETICS PHARMA LLC
- 申请人地址: US WA Mercier Island
- 专利权人: Epigenetics Pharma LLC
- 当前专利权人: Epigenetics Pharma LLC
- 当前专利权人地址: US WA Mercier Island
- 代理机构: Hamilton, Brook, Smith & Reynolds, P.C.
- 国际申请: PCT/US2015/054752 WO 20151008
- 国际公布: WO2016/057825 WO 20160414
- 主分类号: C07H19/10
- IPC分类号: C07H19/10 ; C07H19/20 ; A61K31/7068 ; A61K47/54 ; A61K47/55 ; A61K31/355 ; A61K47/48
摘要:
The present disclosure describes nucleoside and nucleoside analogs that are conjugated to a vitamin E derivative via a phosphate ester or a phosphoramidate linkage. The nucleoside or nucleoside analogs can provide enhanced therapeutic activity (e.g., antiproliferative activity against tumor cells) and/or greater chemical stability in aqueous solutions.
公开/授权文献
- US20170298088A1 Vitamin E-Nucleoside Prodrugs 公开/授权日:2017-10-19